Reports of Guillain-Barre Syndrome After COVID-19 Vaccination in the United States.

ABSTRACT:

Importance

Because of historical associations between vaccines and Guillain-Barré syndrome (GBS), the condition was a prespecified adverse event of special interest for COVID-19 vaccine monitoring.

Objective

To evaluate GBS reports to the Vaccine Adverse Event Reporting System (VAERS) and compare reporting patterns within 21 and 42 days after vaccination with Ad26.COV2.S (Janssen), BNT162b2 (Pfizer-BioNTech), and mRNA-1273 (Moderna) COVID-19 vaccines.

Design, setting, and participants

This retrospective cohort study was conducted using US VAERS reports submitted during December 2020 to January 2022. GBS case reports verified as meeting the Brighton Collaboration case definition for GBS in US adults after COVID-19 vaccination were included.

Exposures

Receipt of

SUBMITTER: Abara WE 

PROVIDER: S-EPMC9892957 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature